After specific modifications and highly efficient liver-specific LDLR gene expression, correction of hypercholesterolemia in LDLR deficient mice has no significant toxicity, thus providing another potential genetic tool for treating FH (Hou et al., 2016). The gene discussed is LDLR; the disease is familial hyperaldosteronism.